Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing–remitting multiple sclerosis in Iranian patients

File Size Format
63979_1.pdf 88Kb Adobe PDF View
Title Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing–remitting multiple sclerosis in Iranian patients
Author Arababadi, Mohammad Kazemi; Mosavi, Reza; Khoramdel, Hossein; Yaghini, Narges; Zarandi, Ebrahim Rezazadeh; Araste, Majid; Pourali, Reza; Nekhei, Zohre; Kennedy, Derek
Journal Name Biomarkers in Medicine
Year Published 2010
Place of publication United Kingdom
Publisher Future Medicine
Abstract Background and aim: Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the development or reoccurrence of multiple sclerosis (MS). This project aimed to evaluate the serum levels of relevant cytokines after therapy with IFN- formulations in MS patients. Material and methods: In this study, blood samples were collected from 70 MS patients undergoing four different types of IFN- formulation treatment and 100 healthy controls. After 24 months of treatment the serum levels of IL-17A, IL-12 and IFN-g and IL-10 in patients and healthy controls were analyzed by ELISA. Finding: Our results showed that serum levels of IL-17A were significantly higher in patients treated with Cinnovex and Anovex when compared to healthy controls. Serum levels of IL-10 were significantly decreased after therapy with Cinnovex, whereas serum levels of IFN- were elevated. No difference in serum levels of IL-12 were detected in patients and controls. Conclusion: Results of our study suggest that Cinnovex and Anovex modulate the immune system less than Rebif and Betaferon in MS patients and that an elevated dosage/regime of Cinnovex and Anovex may be required for better regulation of the immune system in MS patients.
Peer Reviewed Yes
Published Yes
Alternative URI http://dx.doi.org/10.2217/BMM.10.81
Copyright Statement Copyright 2010 Future Medicine Ltd. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal website for access to the definitive, published version.
Volume 4
Issue Number 5
Page from 755
Page to 759
ISSN 1752-0363
Date Accessioned 2010-10-22
Language en_AU
Research Centre Eskitis Institute for Drug Discovery
Faculty Faculty of Science, Environment, Engineering and Technology
Subject Medical Genetics (excl Cancer Genetics)
URI http://hdl.handle.net/10072/34904
Publication Type Journal Articles (Refereed Article)
Publication Type Code c1

Show simple item record

Griffith University copyright notice